Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
2.520
+0.520 (26.00%)
At close: Jul 25, 2025, 4:00 PM
2.580
+0.060 (2.37%)
After-hours: Jul 25, 2025, 7:57 PM EDT

Company Description

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer.

It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The company was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A.
Cellectis logo
CountryFrance
Founded1999
IPO DateFeb 7, 2007
IndustryBiotechnology
SectorHealthcare
Employees222
CEOAndre Choulika

Contact Details

Address:
8, rue de la Croix Jarry
Paris, 75013
France
Phone33 1 81 69 16 00
Websitecellectis.com

Stock Details

Ticker SymbolCLLS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001627281
CUSIP Number15117K103
ISIN NumberUS15117K1034
SIC Code2836

Key Executives

NamePosition
Dr. David J. Sourdive Ph.D.Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC and Manufacturing and Director
Dr. Andre Choulika Ph.D.Co-Founder, Chief Executive Officer and Director
Arthur StrilChief Financial Officer and Chief Business Officer
Valerie CrosPrincipal Financial Officer and Principal Accounting Officer
Jean Charles Epinat Ph.D.Chief Technological Officer
Dr. Philippe Duchateau Ph.D.Chief Scientific Officer
Marie-Bleuenn TerrierGeneral Counsel and Secretary of the Board of Directors
Pascalyne WilsonDirector of Communications
Kyung Nam-WortmanExecutive Vice President and Chief Human Resources Officer
Stephan Reynier M.Sc.Chief Regulatory and Pharmaceutical Compliance Officer

Latest SEC Filings

DateTypeTitle
Jul 11, 2025EFFECTNotice of Effectiveness
Jul 2, 2025F-3Filing
Jun 26, 20256-KReport of foreign issuer
Jun 26, 20256-KReport of foreign issuer
May 21, 20256-KReport of foreign issuer
May 21, 20256-KReport of foreign issuer
May 12, 20256-KReport of foreign issuer
May 12, 20256-KReport of foreign issuer
May 6, 20256-KReport of foreign issuer
Apr 28, 20256-KReport of foreign issuer